Cancer Medicines & Molecular Diagnostics

Own the cancer-care chain from molecular testing and laboratory tools to marketed oncology medicines. The basket pairs established drug franchises with businesses that help identify tumors, select treatments and monitor recurrence, rather than making a single clinical-trial bet. With market breadth mixed, this is a selective healthcare allocation whose opportunity rests on cancer-care adoption rather than an AI-infrastructure rebound; reimbursement, trial outcomes and drug competition remain key risks. Launch basket (equal weight): MRK, ABBV, AMGN, LLY, TMO, BMY, REGN, NTRA, GH, ILMN Rules: 1. No inverse, leveraged or volatility ETFs. 2. Only names tradable at the enrolled brokers (Moomoo): no OTC listings, no dead tickers, nothing on the refused list.